Blar i forfatter "Sarink, Danja"

Viser treff 1-3 av 3

    • Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort. 

      Sarink, Danja; Schock, Helena; Johnson, Theron; Overvad, Kim; Holm, Marianne; Tjønneland, Anne; Boutron-Ruault, Marie-Christine; His, Mathilde; Kvaskoff, Marina; Boeing, Heiner; Lagiou, Pagona; Papatesta, Eleni-Maria; Trichopoulou, Antonia; Palli, Domenico; Pala, Valeria; Mattiello, Amalia; Tumino, Rosario; Sacerdote, Carlotta; Bueno-De-Mesquita, Hendrik Bastiaan; van Gils, Carla H.; Peeters, Petra H.; Weiderpass, Elisabete; Agudo, Antonio; Sánchez, María-José; Chirlaque, Maria-Dolores; Ardanaz, Eva; Amiano, Pilar; Khaw, Kay Tee; Travis, Ruth; Dossus, Laure; Gunter, Mark; Rinaldi, Sabina; Merritt, Melissa; Riboli, Elio; Kaaks, Rudolf; Fortner, Renée T. (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-31)
      Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has ...

    • Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort 

      Fortner, Renée T.; Sarink, Danja; Schock, Helena; Johnson, Theron; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Affret, Aurelie; His, Mathilde; Boutron-Ruault, Marie-Christine; Boeing, Heiner; Trichopoulou, Antonia; Naska, Androniki; Orfanos, Philippos; Palli, Domenico; Sieri, Sabina; Mattiello, Amalia; Tumino, Rosario; Ricceri, Fulvio; Bueno-De-Mesquita, Hendrik Bastiaan; Peeters, Petra H.M.; van Gils, Carla H.; Weiderpass, Elisabete; Lund, Eiliv; Quirós, J. Ramón; Agudo, Antonio; Sánchez, María-José; Chirlaque, María-Dolores; Ardanaz, Eva; Dorronsoro, Miren; Key, Tim; Khaw, Kay-Tee; Rinaldi, Sabina; Dossus, Laure; Gunter, Marc; Merritt, Melissa A.; Riboli, Elio; Kaaks, Rudolf (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-02-08)
      Background:<br>Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.<br>Methods:<br>A case-control ...

    • Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort 

      Sarink, Danja; Schock, Helena; Johnson, Theron; Chang-Claude, Jenny; Overvad, Kim; Olsen, Anja; Tjønneland, Anne; Arveux, Patrick; Fournier, Agnès; Kvaskoff, Marina; Boeing, Heiner; Karakatsani, Anna; Trichopoulou, Antonia; La Vecchia, Carlo; Masala, Giovanna; Agnoli, Claudia; Panico, Salvatore; Tumino, Rosario; Sacerdote, Carlotta; van Gils, Carla H.; Peeters, Petra H.M.; Weiderpass, Elisabete; Agudo, Antonio; Rodríguez-Barranco, Miguel; Huerta, José María; Ardanaz, Eva; Gil, Leire; Kaw, Kay Tee; Schmidt, Julie A.; Dossus, Laure; His, Mathilde; Aune, Dagfinn; Riboli, Elio; Kaaks, Rudolf; Fortner, Renée T. (Journal article; Peer reviewed, 2018-10-22)
      <b>Background</b><br> Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to ...